Health Care [ 9/12 ] | Biotechnology [ 43/73 ]
NASDAQ | Common Stock
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States.
The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair.
It also develops camonsertib (RP-3500), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase that is in Phase 1/2 clinical trial for the treatment of solid tumors; and lunresertib (RP-6306), a selective and potent oral small molecule inhibitor of Protein Kinase Membrane-associated tyrosine-and threonine-specific cdc-2 inhibitory kinase that is in Phase 1/2 clinical trial.
In addition, the company is developing RP-1664, an oral PLK4 inhibitor in Phase 1 clinical trial to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, an inhibitor of adenosinetriphosphatase activity on the helicase domain of DNA polymerase theta that is in Phase 1 clinical trial.
The company has strategic collaborations with Hoffmann-La Roche Inc., F.
HoffmannLa Roche Ltd, Debiopharm InternationalS. A., Bristol-Myers Squibb Company, Ono Pharmaceutical Company Ltd., and New York University.
Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montreal, Canada.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 8, 25 | -0.39 Increased by +52.44% | -0.56 Increased by +30.36% |
| May 13, 25 | -0.71 Decreased by -336.67% | -0.63 Decreased by -12.70% |
| Mar 3, 25 | -0.67 Increased by 0.00% | -0.81 Increased by +17.28% |
| Nov 7, 24 | -0.81 Decreased by -80.00% | -0.87 Increased by +6.90% |
| Aug 7, 24 | -0.82 Decreased by -192.86% | -0.87 Increased by +5.75% |
| May 7, 24 | 0.30 Increased by +136.14% | -0.78 Increased by +138.30% |
| Feb 28, 24 | -0.67 Increased by +10.67% | -0.36 Decreased by -86.11% |
| Nov 9, 23 | -0.45 Decreased by -126.32% | -0.86 Increased by +47.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 250.00 K Decreased by -76.70% | -16.74 M Increased by +51.85% | Decreased by -6.70 K% Decreased by -106.66% |
| Mar 31, 25 | 0.00 Decreased by -100.00% | -30.04 M Decreased by -328.26% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | -53.48 M Decreased by -509.88% | -28.67 M Decreased by -2.29% | Increased by +53.61% Increased by +124.96% |
| Sep 30, 24 | 53.48 M Increased by +2.38 K% | -34.41 M Decreased by -82.24% | Decreased by -64.34% Increased by +92.64% |
| Jun 30, 24 | 1.07 M Decreased by -96.45% | -34.77 M Decreased by -191.09% | Decreased by -3.24 K% Decreased by -8.11 K% |
| Mar 31, 24 | 52.40 M Increased by +822.93% | 13.16 M Increased by +137.67% | Increased by +25.12% Increased by +104.08% |
| Dec 31, 23 | 13.05 M Decreased by -28.31% | -28.03 M Increased by +11.46% | Decreased by -214.84% Decreased by -23.50% |
| Sep 30, 23 | 2.16 M Decreased by -98.08% | -18.88 M Decreased by -125.02% | Decreased by -874.43% Decreased by -1.40 K% |